CD274 and glioblastoma: TNFRSF14 serves as a crucial compensatory mechanism for the acquired resistance of GBM cells to IFN-γ and anti-PD-L1 treatment, and combination blockade of TNFRSF14 and PD-L1 brings improved therapeutic benefits than anti-PD-L1 monotherapy in GBM.